The effect of a radiographic solid fusion on clinical outcomes after minimally invasive transforaminal lumbar interbody
Recombinant human BMP-2 was introduced and approved by the FDA in 2002 as a possible substitute for iliac crest bone graft (ICBG) in anterior lumbar interbody
fusion (ALIF) as it had superior fusion rates (94.5%) compared to those of ICBG (88%) (6-9).
When conservative therapies fail, traditional surgeries from posterior approach are widely used, including microendoscopic decompressive laminotomy for simple DLSS, posterior lumbar interbody
fusion, transforaminal lumbar interbody
fusion, and minimally invasive transforaminal lumbar interbody
fusion for DLSS with lumbar spondylolisthesis or instability.
The clinical consensus of lumbar interbody
fusion is that as far as possible, the posterior tensile structures should be retained and unnecessary trauma should be reduced to ensure postoperative short-term stability and long-term fusion rate [5, 6].
Different circumferential fusion techniques have been described such as combined anterior-posterior fusion (APF), instrumented posterior lumbar interbody
fusion (PLIF) and transforaminal lumbar interbody
Based on surgery type, the market is segmented into Anterior Cervical Discectomy and Fusion (ACDF); Transforamenal Lumbar Interbody
Fusion (TLIF); Anterior Lumbar Interbody
Fusion (ALIF); Lateral Lumbar Interbody
Fusion (LLIF) among others.
A variety of surgical procedures have been used for the management of the disorder; which include Posterior Lumbar Interbody
Fusion (PLIF), Transforaminal Lumbar Interbody
Fusion (TLIF), and posterolateral fusion and Posterior Instrumentation (PLF).
Specific topics include posterior minimally invasive cervical fusion, the lateral retropleural approach for thoracic discectomy and corpectomy, transforaminal lumbar interbody
fusion, axial lumbar interbody
fusion, and surgical graft options and biologics.
cage is made from Zeniva[R] PEEK rod stock that TranS1 offers in various sizes, including widths of 17-mm and 22mm and lengths from 40-mm to 60-mm.
The results suggest that Mesoblast's NeoFuse product comprising allogeneic Mesenchymal Precursor Cells (MPCs) is as effective for interbody
lumbar fusion as the gold standard, bone autograft, without the need for a second surgical procedure and its attendant morbidity risks.
There are anterior, posterior, posterior interbody
and other types of spondylodesis (Dulaev, Yastrebkov, and Orlov, 2000; Markov, Vlasov and Voloshin, 2002; Brantigan, 2000; Cloward, 1963; Liu, Ondra, and Angelos, 2002).
Currently, combined anterior and posterior lumbar fusion often involves anterior interbody
fusion (using either autograft or allograft) and posterior fixation.